<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01306123</url>
  </required_header>
  <id_info>
    <org_study_id>NSB09/17</org_study_id>
    <nct_id>NCT01306123</nct_id>
  </id_info>
  <brief_title>Characterization of Cyanocobalamin in Healthy Voluteers After Intranasal and Intramuscual Administration</brief_title>
  <official_title>An Open, Randomized, Single-dose, Two-way Crossover Study to Characterize the Pharmacokinetic Properties of Cyanocobalamin When Administered as an Intranasal Spray and an Intramuscular Injection to Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swedish Orphan Biovitrum</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swedish Orphan Biovitrum</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to assess the relative bioavailability of Nascobal Nasal
      Spray as compared to an IM injection of cyanocobalamin (European reference product).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, randomized, single-dose, two-way crossover study. The study consists
      of a screening visit, two 4-days confinement periods and a follow-up telephone call. The two
      confinement periods will be separated by a washout period of at least 28 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative bioavailability</measure>
    <time_frame>0-72 hours</time_frame>
    <description>Relative bioavailability (Frel) based on the area under the serum concentration-time curve during 72 hours (AUC0-72h) for the test and reference products.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Additional PK characteristics</measure>
    <time_frame>0-72h</time_frame>
    <description>Maximum serum concentration (Cmax), time of Cmax (tmax) and AUC0-24h.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Focus: Bioavailability</condition>
  <arm_group>
    <arm_group_label>Nascobal nasal spray (cyanocobalamin USP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One single administration of intranasal cyanocobalamin (initially)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin B12-ratiopharm N, injection solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One single injection of IM cyanocobalamin (initially)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nascobal nasal spray (cyanocobalamin, USP)</intervention_name>
    <description>Single intranasal administration</description>
    <arm_group_label>Nascobal nasal spray (cyanocobalamin USP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin B12-ratiopharm N, injection solution</intervention_name>
    <description>One single intramuscular administration</description>
    <arm_group_label>Vitamin B12-ratiopharm N, injection solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy female and male voluteers

          -  18-40 years of age

          -  BMI between 18.5 and 30.0 kg/m2

        Exclusion Criteria:

          -  Females who are pregnant or lactating

          -  History of clinically significant metabolic, hepatic, renal, haematological,
             pulmondary, cardiovascular, gastrointestinal, urological, neurological or phychiatric
             disorders

          -  Serum vitamin B12 &lt;=250 pmol/L or MMA &gt;=0.40 umol/L

          -  Evidence of significant intranasal pathology

          -  Nasal congestion, allergic rhinitis or upper respiratory tract infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nabil Al-Tawil, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Trial Alliance</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karolinska Trial Alliance, Karolinska University Hospital, Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2011</study_first_submitted>
  <study_first_submitted_qc>February 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2011</study_first_posted>
  <last_update_submitted>October 31, 2014</last_update_submitted>
  <last_update_submitted_qc>October 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bioavailability</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>cyanocobalamin</keyword>
  <keyword>intranasal</keyword>
  <keyword>intramuscular</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

